NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Myeloma Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

 



Myeloma

ALLIANCE A061202 - "A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy"

CANCER TYPE: Myeloma
RESEARCH BASE: Alliance
NCT NUMBER: NCT02004275
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 09/26/2018 (20:37:28)

BRIEF DESCRIPTION

MM refractory to lenalidomide and proteasome inhibitor-based therapy; pomalidomide/dexamethasone/ixazomib vs. pomalidomide/dexamethasone






ECOG-ACRIN E1A11 - "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)"

CANCER TYPE: Myeloma
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT01863550
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 07/27/2018 (13:57:05)

BRIEF DESCRIPTION

Multiple myeloma, newly diagnosed, bortezomib, lenalidomide, and dexamethasone vs. carfilzomib, lenalidomide and dexamethazone.  DCP-001 Eligible






SWOG S1702 - "PHASE II STUDY OF ISATUXIMAB (SAR650984) (NSC-795145) FOR PATIENTS WITH PREVIOUSLY TREATED AL AMYLOIDOSIS"

CANCER TYPE: Myeloma
RESEARCH BASE: SWOG
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 11/27/2018 (22:53:11)

BRIEF DESCRIPTION

Relapsed or refractory, AL (Light Chain) Amyloidosis, measurable disease, Isatuximab









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA